OR
Cardiology - Vascular Medicine
Explore the evolving role of endothelin receptor antagonists (ERAs) in contemporary pulmonary arterial hypertension management. This educational infographic reviews the endothelin pathway and key evidence from SERAPHIN and AMBITION supporting long-term outcome improvement and upfront combination therapy. It also examines the 2022 ESC/ERS risk-based treatment framework and the expanding PAH therapeutic landscape with newer pathways such as sotatercept. Learn how early appropriate therapy, multi-pathway targeting, regular risk reassessment and timely escalation shape modern PAH care.
0 Likes
0 Comments
At PAH Pulse, we are committed to advancing scientific understanding and clinical excellence in pulmonary vascular disease. This forum provides a platform for healthcare professionals to explore evolving therapeutic strategies for pulmonary arterial hypertension, supporting individualized patient care.
© 2026 i-rhythm, All Rights Reserved. MSN i-Rhythm does not provide medical advice, diagnosis or treatment.
For unrestricted access to content and a seamless experience,
Complete your profile to help us deliver a more personalized experience.